Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...
Several recent studies have suggested HRT is a risk factor in various conditions, notably Alzheimer's - now UK boffins have ...
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems ...
A groundbreaking study reveals that concussions and repetitive head injuries in sports could trigger latent viruses in the ...
Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...
Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.